Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis

Wang, 2020, A novel coronavirus outbreak of global health concern, Lancet, 395, 470, 10.1016/S0140-6736(20)30185-9 Hu, 2020, Risk factors associated with clinical outcomes in 323 coronavirus disease 2019 (COVID-19) hospitalized patients in Wuhan, China, Clin Infect Dis, 71, 2089, 10.1093/cid/ciaa539 Siordia, 2020, Epidemiology and clinical features of COVID-19: a review of current literature, J Clin Virol, 127, 104357, 10.1016/j.jcv.2020.104357 Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0 Stockman, 2006, SARS: systematic review of treatment effects, PLoS Med, 3, e343, 10.1371/journal.pmed.0030343 GU, 2016, Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature, Intensive Care Med, 42, 829, 10.1007/s00134-015-4095-4 McGee, 2008, Use of corticosteroids in treating infectious diseases, Arch Intern Med, 168, 1034, 10.1001/archinte.168.10.1034 Russell, 2020, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet, 395, 473, 10.1016/S0140-6736(20)30317-2 Shang, 2020, On the use of corticosteroids for 2019-nCoV pneumonia, Lancet, 395, 683, 10.1016/S0140-6736(20)30361-5 Bartoletti, 2021, Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study, Clin Microbiol Infect, 27, 105, 10.1016/j.cmi.2020.09.014 GU, 2007, Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial, Chest, 131, 954, 10.1378/chest.06-2100 Fadel, 2020, Early short-course corticosteroids in hospitalized patients with COVID-19, Clin Infect Dis, 71, 2114, 10.1093/cid/ciaa601 Horby, 2021, Dexamethasone in hospitalized patients with Covid-19, N Engl J Med, 384, 693, 10.1056/NEJMoa2021436 Ye, 2020, Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis, CMAJ, 192, E756, 10.1503/cmaj.200645 So, 2020, High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series, Respirol Case Rep, 8, 10.1002/rcr2.596 Deal, 2008, Role of corticosteroids in the management of acute respiratory distress syndrome, Clin Therapeut, 30, 787, 10.1016/j.clinthera.2008.05.012 Ranieri, 2012, Acute respiratory distress syndrome: the Berlin Definition, JAMA, 307, 2526 Gong, 2020, Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old, J Med Virol, 92, 2551, 10.1002/jmv.26052 Villar, 2020, Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial, Lancet Respir Med, 8, 267, 10.1016/S2213-2600(19)30417-5 Kolilekas, 2020, Can steroids reverse the severe COVID-19 induced "cytokine storm"?, J Med Virol, 92, 2866, 10.1002/jmv.26165 Monedero, 2021, Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study, Crit Care, 25, 2, 10.1186/s13054-020-03422-3 RECOVERY Collaborative Group, 2021, Dexamethasone in hospitalized patients with Covid-19, N Engl J Med, 384, 693, 10.1056/NEJMoa2021436 Li, 2020, Acute respiratory failure in COVID-19: is it “typical” ARDS?, Crit Care, 24, 198, 10.1186/s13054-020-02911-9